(Reuters) - Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder value in face of stiff competition from makers of less-costly generics.Full story
Moody's Investors Service on Tuesday lowered the long-term debt ratings of drug maker Merck & Co. Full story
Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit. Full story
The FMHR traders debate how to play Yum! Brands after the company's China sales fell less-than-expected; and Steve Grasso of Stuart Frankel offers his opinion on whether Merck has more upside ahead.
Merck showed big numbers in this morning's earnings report, with CNBC's Seema Mody.
Merck announced results of a study indicating their new drug, suvorexant, made people fall asleep 40 percent faster and 40 percent longer than placebo without a lingering drowsy feeling upon waking. NBC’s Robert Bazell reports.
This undated handout image, provided by Merck & Co. Inc. on March 9, 2009, shows the cholesterol drug Vytorin. REUTERS/Courtesy of Merck/Handout
A branch of drugs and chemicals group Merck is pictured in central German city of Darmstadt March 7, 2012. REUTERS/Alex Domanski
The logo of drugs and chemicals group Merck is pictured at one of its branches in central German city of Darmstadt March 7, 2012. REUTERS/Alex Domanski
